Synthesis and In Vitro Cytotoxic Activity of Novel 6-Chloro-1,1-dioxo-1,4,2-benzodithiazin-3-ylhydrazine Derivatives

• Autorzy: Pomarancka, E. , Bednarski, P. , Grunert, R. , Brzozowski, Z. , Lach, J.
• Języki publikacji: EN

Abstrakty

EN

The syntheses of 1-(6-chloro-1,1-dioxo-1,4,2-benzodithiazin-3-yl)-4-hydroxysemicarbazides 11-19, hydroxybenzaldehyde N-(6-chloro-7-methyl-1,1-dioxo-1,4,2- benzodithiazin-3-yl)hydrazones 21-24 and 8-chloro-2-(1-naphthylamino)-5,5- dioxo[1,2,4]triazolo[2,3-b][1,4,2]benzodithiazine-7-carbonitrile (26) are described. All compounds were tested for their in vitro cytotoxic potency against 12 human cancer cell lines at the Institute of Pharmacy, University of Greifswald. The compounds 11-19 were inactive, whereas 22 and 24 exhibited weak tumor growth inhibitory properties. The compound 26 was screened at the National Cancer Institute and showed reasonable anticancer activity.

Słowa kluczowe

EN

6-chloro-1,1-dioxo-1,4,2-benzodithiazin-3-ylhydrazine derivatives; cytotoxic activity; syntheses

• Czasopismo: Polish Journal of Chemistry
• Rocznik: 2006
• Tom: Vol. 80, nr 3
• Strony: 429-438
• Opis fizyczny: Bibliogr. 29 poz.

Twórcy

autor

Pomarancka, E.

autor

Bednarski, P.

autor

Grunert, R.

autor

Brzozowski, Z.

autor

Lach, J.

• Department of Chemical Technology of Drugs, Medical University of Gdańsk, Al. Gen. J. Hallera 107, 80-416 Gdańsk, Poland

Bibliografia

• 1. Ren S., Wang R., Komatsu K., Bonaz-Krause R, Zyrianov Y, McKenna Ch.E., Csipke C., Tokes Z.A.and Lien E.J., J. Med. Chem., 45, 410 (2002).
• 2. Shao J., Zhou L., Di Bilio A.J., Su L., Ren S., Lien EJ. and Yen Y, Biochemical Pharmacology, 69,627 (2005).
• 3. Sorg L., Hull W.E., Kliem H.K., Mier W. and Wiessler M., Carbohydrate Res., 340, 181 (2005).
• 4. Nigovič B., Kujundzič N. and Sankovič K., Eur. J. Med. Chem., 40, 51 (2005).
• 5. Mayhew CH.N., Sumpter R., Cibull M., Phillips J.D. and Elford H.L., Antiviral Res., 65, 13 (2005).
• 6. Cecchi A., Winum J., Innocenti A., Yullo D., Montero J., Scozzafava A. and Supuran C.T., Bioorg. Med.Chem. Lett., 14, 5775 (2004).
• 7. Rossello A., Nuti E., Carelli P., Orlandini E., Macchia M., Nencetti S., Zandomeneghi M.F., Balzano M.,Albini A. and Murphy G., Bioorg. Med. Chem. Lett., 15, 1321 (2005).
• 8. Winum J., Pastorekova S., Jakubickova L., Montero J., Scozzafava A., Pastorek J., Yullo D., Innocenti A.and Supuran C.T., Bioorg. Med. Chem. Lett., 15, 579 (2005).
• 9. Turkmen H., Durgun M., Vilmaztekin S., Emul M., Yullo D., Scozzafava A., Innocenti A. and Supuran C.T., Bioorg. Med. Chem. Lett., 15, 367 (2005).
• 10. Pomarnacka E. and Brzozowski Z., Acta Polon. Pharm. Drug Res., 54, 215 (1997).
• 11. Brzozowski Z., Acta Polon. Pharm. Drug Res., 55, 473 (1998).
• 12.   Pomarnacka E. and Kórnicka A., Farmaco, 56, 571 (2001).
• 13. Pomarnacka E. and Kozlarska-Kędra I.,Farmaco, 58, 423 (2003).
• 14. Sławiński J. and Gdaniec M., Eur. J. Med. Chem., 40, 377 (2005).
• 15. Pomarnacka E., Acta Polon. Pharm. Drug Res., 55, 481 (1998).
• l6. Neamati N., Mazumder A., Owen J.M., Schultz R.J., Sunder S. and Pommier V. Antviral Chem. Chemother.,8,485(1991).
• 17. Kuo L.C., Assefa H., Brzozowski Z., Sławiński J., Sączewski F., Buolamwini J.K. and Nemati N., J. Med. Chem., 41, 385 (2004).
• 18. Pomarnacka E., Kórnicka A. and Sączewski F., Heterocycles, 55, 753 (2001).
• 19. Brzozowski Z., Sączewski F. and Gdaniec M., Bioorg. Med. Chem., 11, 3673 (2003).
• 20. Pomarnacka E. and Gdaniec M., Bioorg. Med. Chem., 11, 1259 (2003).
• 21. Brzozowski Z., Sączewski F. and Gdaniec M., Eur. J. Med. Chem., 38, 991 (2003).
• 22. Brzozowski Z. and Sławiński J., Acta Polon Pharm., 41, 5 (1984).
• 23. Brzozowski Z. and Sławiński J., Acta Polon. Pharm., 41, 133 (1984).
• 24. Brzozowski Z., Sławiński J., Gajewski F. and Pomarnacka E., Acta Polon. Pharm. Drug Res., 50, 199 (1993).
• 25. Bernhardt G., Reile H., Birnböck H., SpruB T. and Schönenberger H., J. CancerRes. Clin. Oncol, 118, 35 (1992).
• 26. Pomarnacka E., Bednarski P., GrunertR. and ReszkaP.,Acta Polon.Pharm. Drug Res., 61,461 (2004).
• 27. Details of this system and the information which is encoded by the activity pattern over all cell lines have been also described in our previous paper ref. [26].
• 28. Monks A.P., Scudiero D.A., Skehan P., Shoemaker K.D., Hose C., Langley J., Cronise P., Vaigro-Wolff A., Gray-Goodrich M., Campbell H. and Boyd M., J. Natl. Cancer Inst., 83, 757 (1991).
• 29. Grever M.R., Schepartz S.A. and Chamber B.A., The National Cancer Institute: Cancer Drug Discovery and Development Program. Semin. Oncol., 19, 622 (1992).